logo
Plus   Neg
Share
Email

Regeneron Enters Manufacturing And Supply Deal With BARDA For REGN-COV2

Regeneron Pharmaceuticals, Inc. (REGN) announced it has been awarded a $450 million manufacturing and supply contract to manufacture and supply REGN-COV2 for BARDA and U.S. Department of Defense. The company said the deal supports continued manufacturing so that the product could be made available immediately in the United States if clinical trials are successful and the FDA grants Emergency Use Authorization.

REGN-COV2 is Regeneron's investigational double antibody cocktail that is currently in two Phase 2/3 clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19 infection.

Shares of Regeneron Pharma were up 3% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
H-E-B has issued an all-store recall for Blue Cheese Salmon Burgers citing the presence of an undeclared allergen, the U.S. Food and Drug Administration announced. The products contain wheat, a known allergen, which is not declared on the product label. Consumers with allergy or severe sensitivity to wheat may get serious or life-threatening allergic reaction if they consume these products. The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter. The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases.
Follow RTT